Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127793011 | 12779301 | 1 | I | 20160818 | 20160921 | 20160926 | 20160926 | PER | US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2016-078774 | BRISTOL MYERS SQUIBB | 4.39 | YR | M | Y | 0.00000 | 20160926 | MD | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127793011 | 12779301 | 1 | PS | ABILIFY | ARIPIPRAZOLE | 1 | Unknown | 2.5 MG, QD | U | 21436 | 2.5 | MG | QD | ||||||
| 127793011 | 12779301 | 2 | SS | ABILIFY | ARIPIPRAZOLE | 1 | U | 21436 | |||||||||||
| 127793011 | 12779301 | 3 | SS | ABILIFY | ARIPIPRAZOLE | 1 | U | 21436 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 127793011 | 12779301 | 1 | Autism spectrum disorder |
| 127793011 | 12779301 | 2 | Attention deficit/hyperactivity disorder |
| 127793011 | 12779301 | 3 | Oppositional defiant disorder |
Outcome of event
| no results found |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127793011 | 12779301 | Off label use | |
| 127793011 | 12779301 | Wrong technique in product usage process |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127793011 | 12779301 | 1 | 20160818 | 0 |